Mechanisms and Therapeutic Prospects of Diabetic Cardiomyopathy Through the Inflammatory Response
The incidence of heart failure (HF) continues to increase rapidly in patients with diabetes. It is marked by myocardial remodeling, including fibrosis, hypertrophy, and cell death, leading to diastolic dysfunction with or without systolic dysfunction. Diabetic cardiomyopathy (DCM) is a distinct myoc...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-06-01
|
| Series: | Frontiers in Physiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphys.2021.694864/full |
| _version_ | 1818571863700275200 |
|---|---|
| author | Namrita Kaur Yingshu Guan Rida Raja Andrea Ruiz-Velasco Wei Liu |
| author_facet | Namrita Kaur Yingshu Guan Rida Raja Andrea Ruiz-Velasco Wei Liu |
| author_sort | Namrita Kaur |
| collection | DOAJ |
| description | The incidence of heart failure (HF) continues to increase rapidly in patients with diabetes. It is marked by myocardial remodeling, including fibrosis, hypertrophy, and cell death, leading to diastolic dysfunction with or without systolic dysfunction. Diabetic cardiomyopathy (DCM) is a distinct myocardial disease in the absence of coronary artery disease. DCM is partially induced by chronic systemic inflammation, underpinned by a hostile environment due to hyperglycemia, hyperlipidemia, hyperinsulinemia, and insulin resistance. The detrimental role of leukocytes, cytokines, and chemokines is evident in the diabetic heart, yet the precise role of inflammation as a cause or consequence of DCM remains incompletely understood. Here, we provide a concise review of the inflammatory signaling mechanisms contributing to the clinical complications of diabetes-associated HF. Overall, the impact of inflammation on the onset and development of DCM suggests the potential benefits of targeting inflammatory cascades to prevent DCM. This review is tailored to outline the known effects of the current anti-diabetic drugs, anti-inflammatory therapies, and natural compounds on inflammation, which mitigate HF progression in diabetic populations. |
| first_indexed | 2024-12-14T18:49:54Z |
| format | Article |
| id | doaj.art-5bff189c86b445d19bc165202566f704 |
| institution | Directory Open Access Journal |
| issn | 1664-042X |
| language | English |
| last_indexed | 2024-12-14T18:49:54Z |
| publishDate | 2021-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Physiology |
| spelling | doaj.art-5bff189c86b445d19bc165202566f7042022-12-21T22:51:17ZengFrontiers Media S.A.Frontiers in Physiology1664-042X2021-06-011210.3389/fphys.2021.694864694864Mechanisms and Therapeutic Prospects of Diabetic Cardiomyopathy Through the Inflammatory ResponseNamrita KaurYingshu GuanRida RajaAndrea Ruiz-VelascoWei LiuThe incidence of heart failure (HF) continues to increase rapidly in patients with diabetes. It is marked by myocardial remodeling, including fibrosis, hypertrophy, and cell death, leading to diastolic dysfunction with or without systolic dysfunction. Diabetic cardiomyopathy (DCM) is a distinct myocardial disease in the absence of coronary artery disease. DCM is partially induced by chronic systemic inflammation, underpinned by a hostile environment due to hyperglycemia, hyperlipidemia, hyperinsulinemia, and insulin resistance. The detrimental role of leukocytes, cytokines, and chemokines is evident in the diabetic heart, yet the precise role of inflammation as a cause or consequence of DCM remains incompletely understood. Here, we provide a concise review of the inflammatory signaling mechanisms contributing to the clinical complications of diabetes-associated HF. Overall, the impact of inflammation on the onset and development of DCM suggests the potential benefits of targeting inflammatory cascades to prevent DCM. This review is tailored to outline the known effects of the current anti-diabetic drugs, anti-inflammatory therapies, and natural compounds on inflammation, which mitigate HF progression in diabetic populations.https://www.frontiersin.org/articles/10.3389/fphys.2021.694864/fulldiabetes mellitusinflammationdiabetic cardiomyopathytreatmentheart failure |
| spellingShingle | Namrita Kaur Yingshu Guan Rida Raja Andrea Ruiz-Velasco Wei Liu Mechanisms and Therapeutic Prospects of Diabetic Cardiomyopathy Through the Inflammatory Response Frontiers in Physiology diabetes mellitus inflammation diabetic cardiomyopathy treatment heart failure |
| title | Mechanisms and Therapeutic Prospects of Diabetic Cardiomyopathy Through the Inflammatory Response |
| title_full | Mechanisms and Therapeutic Prospects of Diabetic Cardiomyopathy Through the Inflammatory Response |
| title_fullStr | Mechanisms and Therapeutic Prospects of Diabetic Cardiomyopathy Through the Inflammatory Response |
| title_full_unstemmed | Mechanisms and Therapeutic Prospects of Diabetic Cardiomyopathy Through the Inflammatory Response |
| title_short | Mechanisms and Therapeutic Prospects of Diabetic Cardiomyopathy Through the Inflammatory Response |
| title_sort | mechanisms and therapeutic prospects of diabetic cardiomyopathy through the inflammatory response |
| topic | diabetes mellitus inflammation diabetic cardiomyopathy treatment heart failure |
| url | https://www.frontiersin.org/articles/10.3389/fphys.2021.694864/full |
| work_keys_str_mv | AT namritakaur mechanismsandtherapeuticprospectsofdiabeticcardiomyopathythroughtheinflammatoryresponse AT yingshuguan mechanismsandtherapeuticprospectsofdiabeticcardiomyopathythroughtheinflammatoryresponse AT ridaraja mechanismsandtherapeuticprospectsofdiabeticcardiomyopathythroughtheinflammatoryresponse AT andrearuizvelasco mechanismsandtherapeuticprospectsofdiabeticcardiomyopathythroughtheinflammatoryresponse AT weiliu mechanismsandtherapeuticprospectsofdiabeticcardiomyopathythroughtheinflammatoryresponse |